Daniel M. Sullivan
Impact in
- Oncology top 0.5%
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Papers in
-
- Cancer therapeutics and mechanisms 37
- Protein Degradation and Inhibitors 27
- Ubiquitin and proteasome pathways 14
- Nuclear Structure and Function 14
- Histone Deacetylase Inhibitors Research 13
- Oncology 76
- Cancer Treatment and Pharmacology 22
- Co-authors
- Joel G. Turner (33 shared papers)Pamela N. Münster (19 shared papers)Adil Daud (16 shared papers)Jana L. Dawson (25 shared papers)Douglas C. Marchion (11 shared papers)Elona Biçaku (9 shared papers)Warren E. Ross (6 shared papers)Susan Minton (13 shared papers)
- Journals
- Blood (40 papers)Journal of Clinical Oncology (32 papers)Clinical Cancer Research (19 papers)Cancer Research (14 papers)Biochemistry (7 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Daniel M. Sullivan
234 papers receiving 9.7k citations
Daniel M. Sullivan's Hit Papers
Peers
Comparison fields: 5 of 158
- Oncology 2.8k
- Hematology 1.2k
- Biological Psychiatry 219
- Physiology 431
- Molecular Biology 5.5k
Countries citing papers authored by Daniel M. Sullivan
This map shows the geographic impact of Daniel M. Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Sullivan more than expected).
Fields of papers citing papers by Daniel M. Sullivan
This network shows the impact of papers produced by Daniel M. Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Sullivan. The network helps show where Daniel M. Sullivan may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel M. Sullivan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 241 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. Hit paper breakdown → | 2006 | 571 |
| 2 | Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Hit paper breakdown → | 2008 | 570 |
| 3 | 2006 | 478 | |
| 4 | 2011 | 458 | |
| 5 | 1994 | 392 | |
| 6 | 2011 | 284 | |
| 7 | 2006 | 210 | |
| 8 | 2000 | 201 | |
| 9 | 2007 | 198 | |
| 10 | 2005 | 179 | |
| 11 | 1986 | 164 | |
| 12 | 2004 | 163 | |
| 13 | 2006 | 161 | |
| 14 | 2007 | 157 | |
| 15 | 2014 | 154 | |
| 16 | 2014 | 151 | |
| 17 | Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. | 1987 | 139 |
| 18 | 2000 | 136 | |
| 19 | 1983 | 136 | |
| 20 | 2008 | 131 |
About Daniel M. Sullivan
Daniel M. Sullivan is a scholar working on Molecular Biology, Oncology, Hematology, Pulmonary and Respiratory Medicine and Infectious Diseases, having authored 241 papers that have together received 10.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (50 papers), Cancer therapeutics and mechanisms (37 papers), Protein Degradation and Inhibitors (27 papers), Cancer Treatment and Pharmacology (22 papers), Ubiquitin and proteasome pathways (14 papers), Nuclear Structure and Function (14 papers), HIV/AIDS drug development and treatment (13 papers) and Histone Deacetylase Inhibitors Research (13 papers). The work is most often cited by research in Oncology (2.8k citations), Hematology (1.2k citations), Biological Psychiatry (219 citations), Physiology (431 citations) and Molecular Biology (5.5k citations). Daniel M. Sullivan has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Joel G. Turner, Pamela N. Münster, Adil Daud, Jana L. Dawson, Douglas C. Marchion, Elona Biçaku, Warren E. Ross, Susan Minton, William S. Dalton and Michael D. Latham. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Cancer Research, Cancer Research and Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.